# EDGAR Filing Document

**Accession Number:** 0002076615
**File Stem:** 0001193125-25-182790
**Filing Date:** 2025-8
**Character Count:** 19508
**Document Hash:** d9f0413169af5d2ae303c356bbf3eb63
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-182790.hdr.sgml**: 20250818

**ACCESSION NUMBER**: 0001193125-25-182790

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20250818

**DATE AS OF CHANGE**: 20250818

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BridgeBio Oncology Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001869105
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94447
- **FILM NUMBER:** 251229021

**BUSINESS ADDRESS:**
- **STREET 1:** 256 E. GRAND AVENUE, SUITE 104
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 857 702 0377

**MAIL ADDRESS:**
- **STREET 1:** 256 E. GRAND AVENUE, SUITE 104
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Helix Acquisition Corp. II
- **DATE OF NAME CHANGE:** 20210623
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BridgeBio Pharma LLC
- **CENTRAL INDEX KEY:** 0002076615

**ORGANIZATION NAME:**
- **EIN:** 811790983
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** C/O BRIDGEBIO PHARMA, INC.
- **STREET 2:** 3160 PORTER DRIVE, SUITE 250
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
- **BUSINESS PHONE:** (650) 391-9740

**MAIL ADDRESS:**
- **STREET 1:** C/O BRIDGEBIO PHARMA, INC.
- **STREET 2:** 3160 PORTER DRIVE, SUITE 250
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304

## Exhibit 99.1

Exhibit 99.1

**Joint Filing Agreement**

The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

---

| | |
|:---|:---|
| **BridgeBio Pharma LLC** | **BridgeBio Pharma LLC** |
| Signature: | /s/ Neil Kumar |
| Name/Title: | Neil Kumar, Chief Executive Officer |
| Date: | August 18, 2025 |
| **BridgeBio Pharma, Inc.** | **BridgeBio Pharma, Inc.** |
| Signature: | / s/ Neil Kumar |
| Name/Title: | Neil Kumar, Chief Executive Officer |
| Date: | August 18, 2025 |

---

ACTIVE/201354583.2

------

## Ex-99.A

**SCHEDULE A**

**1.** **BridgeBio Pharma, Inc.**

The name, business address, title, present principal occupation or employment of each of the directors and executive officers of BridgeBio Pharma, Inc., a Delaware corporation ("BBIO"), are set forth below. If no business address is given, the director's or executive officer's business address is 3160 Porter Dr, Suite 250, Palo Alto, CA 94304. Unless otherwise indicated, each occupation set forth opposite an individual's name refers to BBIO. Unless otherwise indicated below, all of the persons listed below are citizens of the United States of America.

---

| | |
|:---|:---|
| **Name** | **Present Principal Occupation Including Name and Address of Employer** |
| Neil Kumar, Ph.D. | &nbsp;&nbsp;&nbsp;Director, Chief Executive Officer |
| Eric Aguiar, M.D. | Director; Partner at Aisling Capital - 489 5th Ave 10th Floor, New York, NY 10017 |
| Jennifer E. Cook | Director; Jennifer Cook Consulting |
| Douglas A. Dachille | Director |
| Ronald J. Daniels | Director; President, Johns Hopkins University - 242 Garland Hall, 3400 N. Charles St., Baltimore, MD 21218 |
| Andrea J. Ellis | Director; Chief Financial Officer of Fanatics Betting & Gaming – 95 Morton Street, New Yor, NY 10014 |
| Fred Hassan | &nbsp;&nbsp;&nbsp;Director |
| Charles Homcy, M.D. | &nbsp;&nbsp;&nbsp;Director |
| Andrew W. Lo, Ph.D. | Director; Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of the MIT Laboratory for Financial Engineering, a principal investigator at the MIT Computer Science and Artificial Intelligence Laboratory - 100 Main St, Cambridge, MA 02142 |
| Frank P. McCormick, Ph.D., F.R.S., D.Sc. | &nbsp;&nbsp;&nbsp;Director, Chairman of Oncology |
| James C. Momtazee | Director; Managing Partner of Patient Square Capital, LP - 2884 Sand Hill Rd #100, Menlo Park, CA 94025 |
| Ali J. Satvat | Director; Partner, Head of Health Care Strategic Growth - 2800 Sand Hill Road, Suite 200, Menlo Park, CA 94025 |
| Randal W. Scott, Ph.D. | Director; Chairman and CEO of Genomic Life - 3344 N Torrey Pines Ct, La Jolla, CA 92037 |
| Hannah A. Valantine, M.D. | Director; Professor of Medicine at Stanford University School of Medicine - 291 Campus Drive, Stanford, CA 94305 |
| **Name** | **Present Principal Occupation Including Name and Address of Employer** |
| &nbsp;&nbsp;&nbsp;*Executive Officers*<br>*(Who Are Not Directors)* |  |
| Thomas Trimarchi, Ph.D. | &nbsp;&nbsp;&nbsp;President and Chief Financial Officer |

---

------

ACTIVE/201359553.3

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**BridgeBio Oncology Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value**

*(Title of Class of Securities)*

**107924102**

*(CUSIP Number)*

**Neil Kumar**<br>c/o BridgeBio Pharma, Inc.<br>3160 Porter Suite 250<br>Palo Alto CA 94304<br>(650) 391-9740

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**08/11/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **107924102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BridgeBio Pharma LLC** | Name of reporting person<br>**BridgeBio Pharma LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**13878554.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**13878554.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**13878554.00** | Aggregate amount beneficially owned by each reporting person<br>**13878554.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**17.5%** | Percent of class represented by amount in Row (11)<br>**17.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **107924102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BridgeBio Pharma, Inc.** | Name of reporting person<br>**BridgeBio Pharma, Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**13878554.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**13878554.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**13878554.00** | Aggregate amount beneficially owned by each reporting person<br>**13878554.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**17.5%** | Percent of class represented by amount in Row (11)<br>**17.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value

**(b) Name of Issuer:**
BridgeBio Oncology Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
256 E. Grand Avenue, Suite 104, South San Francisco, CA, 94080

**Item 4. Purpose of Transaction**

The Reporting Persons acquired the Shares for investment purposes in the ordinary course of business.

Immediately following the Effective Time of the Business Combination, Neil Kumar, Ph.D., Chief Executive Officer and a member of the board of directors of BBIO, and Frank P. McCormick, Ph.D., F.R.S., D.Sc., Chairman of Oncology and a member of the board of directors of BBIO, were appointed to serve as directors of the Issuer.

As a result of their positions, Drs. Kumar and McCormick may, from time to time, engage in discussions with the Issuer's board of directors, management, or other stockholders regarding matters relating to the Issuer's business, operations, governance, strategy, or capital structure. These discussions may include, but are not limited to: (i) the acquisition or disposition of securities of the Issuer; (ii) potential changes to the Issuer's board or management; (iii) strategic transactions, including mergers, acquisitions, or dispositions; or (iv) other matters described in paragraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons may also participate in discussions regarding the Issuer's strategic direction, including potential financing activities, collaborations, or licensing transactions.

In connection with the foregoing, and as may be appropriate from time to time, the Reporting Persons may consider the feasibility and advisability of various alternative courses of action with respect to their investment in the Issuer, including, without limitation: (a) the acquisition or disposition by the Reporting Persons of the Shares, including through derivative transactions which may include security-based swaps and short sales; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) changes in the present board of directors or management of the Issuer; (e) a material change in the present capitalization or dividend policy of the Issuer; (f) other material changes in the Issuer's business or corporate structure; (g) changes in the Issuer's articles of incorporation or bylaws or other actions that may impede the acquisition of control of the Issuer by any person; (h) causing any class of the Issuer's securities to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) causing a class of equity securities of the Issuer to become eligible for termination of registration pursuant to Section 12 of the Exchange Act; or (j) any other action similar to those enumerated above. The Reporting Persons may also propose or support changes to the Issuer's corporate governance policies, board composition, or executive compensation practices, consistent with their investment oversight responsibilities. Except as described in this Item 5 and Item 6, and except for any plans or proposals that may be discussed or considered by Issuer's board of directors, including Drs. Kumar and McCormick in their fiduciary capacities as directors, the Reporting Persons do not currently have any plans or proposals that relate to or would result in any of the actions specified in clauses (a) through (j) of this paragraph.

The Reporting Persons intend to review their investment in the Issuer on a continuing basis and may, depending on various factors - including the Issuer's financial condition, business, operations, prospects, and strategic direction, as well as general economic and industry conditions, the securities markets in general and those for the Issuer's stock in particular, as well as other developments - determine to take additional actions with respect to their investment in the Issuer.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 79,196,710 shares of Common Stock outstanding following the Closing, as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on August 13, 2025.

BBIO LLC is the direct beneficial owner of the Shares, representing approximately 17.5% of the outstanding shares of Common Stock. BBIO as the sole member and parent entity of BBIO LLC may be deemed to beneficially own the Shares held by BBIO LLC. Voting and investment power over the shares held by BBIO LLC is exercised by BBIO. None of the members of the board of directors of BBIO or BBIO LLC has individual voting or investment power with respect to such Shares.

**(b)**
Each of BBIO LLC and BBIO may be deemed to have sole power to direct the vote and disposition of the Shares held directly by BBIO LLC.

**(c)**
Information with respect to all transactions in the shares of Common Stock beneficially owned by the Reporting Persons that were effected during the past sixty days is set forth in Item 3 and incorporated herein by reference.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information contained in Item 3 is incorporated herein by reference.

Lock-Up Agreement

Pursuant to the terms of the Business Combination Agreement, the Reporting Persons agreed, subject to certain customary exceptions, not to (i) sell, offer to sell, contract or agree to sell, pledge or otherwise dispose of, directly or indirectly, any shares of Common Stock held by them (such shares, together with any securities convertible into or exchangeable for or representing the rights to receive shares of Common Stock if any, acquired during the Lock-Up Period (as defined below), the "Lock-Up Shares"), (ii) enter into a transaction that would have the same effect, (iii) enter into any swap, hedge or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Lock-Up Shares or otherwise or engage in any short sales or other arrangement with respect to the Lock-Up Shares or (iv) publicly announce any intention to effect any transaction specified in clause (i) or (ii) until the date that is one year after the later of (x) the filing of the Form 10 Information (as defined in Rule 144(i)(3) of the Securities Act of 1933, as amended) with the U.S. Securities and Exchange Commission (the "SEC") and (y) the Closing Date (the "Lock-Up Period").

The Lock-Up Agreement is also incorporated into the Issuer's Bylaws and applies to all shares received in the merger of Merger Sub with and into Old BBOT, with Old BBOT surviving the merger as a wholly-owned subsidiary of Helix (the "Merger"), or upon the exercise of equity awards assumed by the Issuer in connection with the Business Combination. Permitted transfers include, among others, transfers to affiliates, family members, trusts, or in connection with estate planning. In addition, if the Issuer's board of directors waives or repeals the lock-up for any holder, it must also waive or repeal the lock-up for all similarly situated holders.

Amended and Restated Registration Rights Agreement

On August 11, 2025, in connection with the closing of the Business Combination, the Issuer and certain securityholders, including the Reporting Person, entered into an Amended and Restated Registration Rights Agreement (the "Registration Rights Agreement"). Pursuant to the Registration Rights Agreement, the Reporting Person was granted certain demand, shelf, and "piggyback" registration rights with respect to its shares of Common Stock, subject to customary conditions and limitations. The Registration Rights Agreement also restricts the ability of the Reporting Person to transfer its shares for a period following the closing of the Business Combination, as specified in the Company's Bylaws, subject to certain permitted transfers. The Registration Rights Agreement also provides for customary indemnification and contribution provisions.

The foregoing descriptions of the Lock-Up Agreement and Amended and Restated Registration Rights Agrement contained herein do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, which are attached hereto as Exhibits 99.3 and 99.4, respectively, and are incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BridgeBio Pharma LLC

**Signature:** /s/ Neil Kumar

**Name/Title:** Neil Kumar, Chief Executive Officer

**Date:** 08/18/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BridgeBio Pharma, Inc.

**Signature:** /s/ Neil Kumar

**Name/Title:** Neil Kumar, Chief Executive Officer

**Date:** 08/18/2025